• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature . Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

tetano

Editor, Senior Moderator
Nature


. 2025 Feb 5.
doi: 10.1038/s41586-024-08511-9. Online ahead of print. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

Hiam Chemaitelly[SUP] 1 2 3 [/SUP], Houssein H Ayoub[SUP] 4 [/SUP], Peter Coyle[SUP] 5 6 7 [/SUP], Patrick Tang[SUP] 8 [/SUP], Mohammad R Hasan[SUP] 9 [/SUP], Hadi M Yassine[SUP] 5 10 [/SUP], Asmaa A Al Thani[SUP] 5 10 [/SUP], Zaina Al-Kanaani[SUP] 6 [/SUP], Einas Al-Kuwari[SUP] 6 [/SUP], Andrew Jeremijenko[SUP] 6 [/SUP], Anvar Hassan Kaleeckal[SUP] 6 [/SUP], Ali Nizar Latif[SUP] 6 [/SUP], Riyazuddin Mohammad Shaik[SUP] 6 [/SUP], Hanan F Abdul-Rahim[SUP] 11 [/SUP], Gheyath K Nasrallah[SUP] 5 10 [/SUP], Mohamed Ghaith Al-Kuwari[SUP] 12 [/SUP], Adeel A Butt[SUP] 13 6 14 [/SUP], Hamad Eid Al-Romaihi[SUP] 15 [/SUP], Mohamed H Al-Thani[SUP] 15 [/SUP], Abdullatif Al-Khal[SUP] 6 [/SUP], Roberto Bertollini[SUP] 15 [/SUP], Laith J Abu-Raddad[SUP] 16 17 18 19 20 [/SUP]



Affiliations
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved over short timescales, leading to the emergence of more transmissible variants such as Alpha and Delta[SUP]1-3[/SUP]. The arrival of the Omicron variant marked a major shift, introducing numerous extra mutations in the spike gene compared with earlier variants[SUP]1,2[/SUP]. These evolutionary changes have raised concerns regarding their potential impact on immune evasion, disease severity and the effectiveness of vaccines and treatments[SUP]1,3[/SUP]. In this epidemiological study, we identified two distinct patterns in the protective effect of natural infection against reinfection in the Omicron versus pre-Omicron eras. Before Omicron, natural infection provided strong and durable protection against reinfection, with minimal waning over time. However, during the Omicron era, protection was robust only for those recently infected, declining rapidly over time and diminishing within a year. These results demonstrate that SARS-CoV-2 immune protection is shaped by a dynamic interaction between host immunity and viral evolution, leading to contrasting reinfection patterns before and after Omicron's first wave. This shift in patterns suggests a change in evolutionary pressures, with intrinsic transmissibility driving adaptation pre-Omicron and immune escape becoming dominant post-Omicron, underscoring the need for periodic vaccine updates to sustain immunity.


 
Back
Top Bottom